 | Up a level |
Sathekge, Mike M; Lawal, Ismaheel O; Bal, Chandrasekhar; Bruchertseifer, Frank; Ballal, Sajana; Cardaci, Giuseppe; Davis, Cindy; Eiber, Mathias; Hekimsoy, Türkay; Knoesen, Otto; Kratochwil, Clemens; Lenzo, Nat P; Mahapane, Johncy; Maserumule, Letjie C; Mdlophane, Amanda H; Mokoala, Kgomotso M G; Ndlovu, Honest; Pant, Vineet; Rathke, Hendrik; Reed, Janet; ... (2024). Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. The Lancet. Oncology, 25(2), pp. 175-183. Elsevier 10.1016/S1470-2045(23)00638-1
Krolicki, Leszek; Kunikowska, Jolanta; Cordier, Dominik; Slavova, Nedelina; Koziara, Henryk; Bruchertseifer, Frank; Maecke, Helmut R; Morgenstern, Alfred; Merlo, Adrian (2023). Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm? International journal of molecular sciences, 24(21) MDPI 10.3390/ijms242115701
Wild, Damian; Frischknecht, Michael; Zhang, Hanwen; Morgenstern, Alfred; Bruchertseifer, Frank; Boisclair, Julie; Provencher-Bolliger, Anne; Reubi, Jean-Claude; Maecke, Helmut R (2011). Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer research, 71(3), pp. 1009-18. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-10-1186
